Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2022-08-12 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
信息披露管理制度（2022年8月）
Governance Information Classification · 95% confidence The document is titled "深圳华大基因股份有限公司 信息披露管理制度" which translates to "Shenzhen BGI Genomics Co., Ltd. Information Disclosure Management System." It is a detailed internal policy document outlining the principles, rules, and procedures for information disclosure by the company. It references various laws and regulations such as the Company Law, Securities Law, Shenzhen Stock Exchange rules, and China Securities Regulatory Commission requirements. The content covers definitions of information disclosure, types of reports (annual, interim, quarterly), disclosure obligations, procedures for major events, related party transactions, and other compliance matters. It is a governance and compliance manual rather than a financial report, earnings release, or announcement. It does not contain financial statements or results but rather the framework for how the company manages and discloses information to the market and regulators. Therefore, the document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-08-12 Chinese
募集资金管理办法（2022年8月）
Capital/Financing Update Classification · 95% confidence The document is titled '募集资金管理办法' which translates to 'Fundraising Capital Management Measures' and is issued by Shenzhen BGI Genomics Co., Ltd. It details the management, use, supervision, and disclosure requirements related to the company's raised funds. The content includes regulatory references, internal control procedures, usage restrictions, reporting obligations, and oversight mechanisms for the use of funds raised through stock issuance. It is a detailed policy or procedural document rather than a financial report, earnings release, or announcement. It does not contain financial statements or results but focuses on governance and compliance related to capital raised. This aligns best with the category 'Capital/Financing Update (CAP)' as it pertains to the management and use of capital raised by the company. The document length (9610 characters) and detailed procedural content confirm it is not a brief announcement or a report publication notice. Therefore, the classification is CAP with high confidence.
2022-08-12 Chinese
投资者关系管理制度（2022年8月）
Governance Information Classification · 95% confidence The document is titled "深圳华大基因股份有限公司 投资者关系管理制度" which translates to "Investor Relations Management System" of Shenzhen BGI Genomics Co., Ltd. It is a detailed policy document outlining the company's investor relations management principles, responsibilities, communication channels, voluntary disclosure practices, investor complaint handling, and related governance. It references compliance with laws such as the Company Law and Securities Law, and regulatory guidelines. The document is a governance and procedural manual rather than a financial report, earnings release, or announcement. It does not contain financial statements, audit opinions, voting results, or capital changes. It is not a presentation or transcript of calls. It is a governance-related document detailing internal rules and practices for investor relations management. Therefore, the most appropriate classification is Governance Information (CGR). The document length (9607 characters) and content support this classification with high confidence.
2022-08-12 Chinese
关于拟与关联方联合竞买及合作建设盐田区J402-0349地块的关联交易公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Shenzhen BGI Genomics Co., Ltd. regarding a proposed related-party transaction involving joint bidding and cooperative construction of a land parcel (J402-0349) with related parties. It includes extensive information about the transaction, the parties involved, financial data of related entities, the terms of the joint bidding and construction agreement, risk disclosures, and approvals from the board, independent directors, and supervisory board. The document is a formal announcement of a significant related-party transaction and investment project, including governance and compliance details. It does not contain financial statements, earnings data, or audit opinions, nor is it a transcript or presentation. It is not a report publication announcement since it is substantive and lengthy (over 12,000 characters) and contains detailed transaction information. The document fits best into the category of Regulatory Filings (RNS) as a general regulatory announcement about a related-party transaction and investment project that does not fit into more specific categories like Capital/Financing Update or M&A Activity. Therefore, the classification is RNS with high confidence.
2022-08-12 Chinese
规范关联方资金往来管理制度（2022年8月）
Governance Information Classification · 95% confidence The document is titled '规范关联方资金往来管理制度' which translates to 'Regulation on Related Party Fund Transactions Management System' for Shenzhen BGI Genomics Co., Ltd. It outlines internal policies and procedures regarding related party transactions, fund management, auditing, and responsibilities. There are no financial statements, earnings data, or report summaries. It is a governance or internal control policy document rather than a financial report or announcement. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is not a regulatory filing or announcement but a governance-related document detailing internal rules and procedures. Therefore, the best fitting category is Governance Information (CGR). The document length is 4101 characters, which is substantive enough to be a full policy document rather than a brief announcement.
2022-08-12 Chinese
关于向武汉华大吉诺因生物科技有限公司增资暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a capital increase (增资) by Shenzhen BGI Genomics Co., Ltd. into Wuhan BGI Genomics Bio-Technology Co., Ltd., which is an affiliated transaction (关联交易). It includes extensive information about the transaction overview, the target company's business and financial status, the shareholders' structure before and after the transaction, related parties' information, and evaluation reports. The document is a formal announcement of a financing transaction involving capital injection and related party disclosures. It is not a full financial report, earnings release, or management discussion, but rather a capital/financing update about a specific investment transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a full announcement, not a brief notice or report publication announcement.
2022-08-12 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.